{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:31:23Z","timestamp":1788395483724,"version":"build-2803163510"},"reference-count":33,"publisher":"Tech Science Press","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["oncol res"],"published-print":{"date-parts":[[2021,9,7]]},"abstract":"<jats:p>Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecan-induced diarrhea is intestinal mucosal damage caused by SN-38 (active\n metabolite of irinotecan) hydrolyzed from SN-38G (inactive metabolite) by bacterial -glucuronidase (G). According to an animal study, silymarin reduces the activity of bacterial G without impairing antitumor efficacy. We conducted a prospective open-label pilot study to evaluate the effect\n of silymarin as supplementation in reducing toxicities of mCRC patients undergoing irinotecan-based chemotherapy. We enrolled and randomized 70 mCRC patients receiving first-line FOLFIRI (5-fluorouracil\/leucovorin\/irinotecan) plus bevacizumab. In each treatment cycle, the study group was administered\n silymarin capsules (150 mg) three times daily for 7 days. The study group experienced less AEs in diarrhea (5.7% vs. 14.6%, <jats:italic>p<\/jats:italic>=0.002) and nausea (27.0% vs. 40.2%, <jats:italic>p<\/jats:italic>=0.005) in comparison with the control group, but no significant differences in hepatic toxicities were observed.\n In conclusion, simultaneous administration of silymarin is a potential effective supplementation for reducing toxicities in mCRC patients undergoing first-line FOLFIRI plus bevacizumab, especially in diarrhea and nausea.<\/jats:p>","DOI":"10.3727\/096504021x16218531628569","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T09:19:40Z","timestamp":1623057580000},"page":"801-809","source":"Crossref","is-referenced-by-count":18,"title":["A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab"],"prefix":"10.32604","volume":"28","author":[{"given":"Tsung-Kun","family":"Chang","sequence":"first","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chieh","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kaohsiung Municipal Tatung Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chih","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Lin","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wen","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chun","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Jung","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Jen","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Hsiang","family":"Chuang","sequence":"additional","affiliation":[{"name":"Graduate Institute of Pharmacognosy, Taipei Medical UniversityTaipeiTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Lu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Center for Biomarkers and Biotech Drugs, Kaohsiung Medical UniversityKaohsiungTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaw-Yuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","reference":[{"key":"b1","volume-title":"Product Information: CAMPTOSAR (R) intravenous injection, irinotecan intravenous injection","year":"2014"},{"key":"b2","first-page":"72","article-title":"Gastrointestinal toxicity or irinotecan","volume":"12","year":"1998","journal-title":"Oncology (Williston Park)"},{"issue":"7","key":"b3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/1389450111314070007","article-title":"Therapeutic targeting of CPT-11 induced diarrhea: A case for prophylaxis","volume":"14","year":"2013","journal-title":"Curr Drug Targets"},{"issue":"8","key":"b4","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1998.16.8.2745","article-title":"Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment","volume":"16","year":"1998","journal-title":"J Clin Oncol."},{"issue":"1","key":"b5","doi-asserted-by":"crossref","first-page":"e83644","DOI":"10.1371\/journal.pone.0083644","article-title":"The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats","volume":"9","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"b6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00280-007-0570-0","article-title":"Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: Implications for the pathobiology of mucositis","volume":"62","year":"2008","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"b7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00280-008-0855-y","article-title":"Irinotecan-induced mucositis is associated with changes in intestinal mucins","volume":"64","year":"2009","journal-title":"Cancer Chemother Pharmacol."},{"issue":"5","key":"b8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2613.2009.00671.x","article-title":"Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile","volume":"90","year":"2009","journal-title":"Int J Exp Pathol."},{"issue":"4","key":"b9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s002800050818","article-title":"Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats","volume":"42","year":"1998","journal-title":"Cancer Chemother Pharmacol."},{"issue":"5","key":"b10","first-page":"1136","article-title":"Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients","volume":"7","year":"2001","journal-title":"Clin Cancer Res."},{"key":"b11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.phrs.2018.10.029","article-title":"Pharmacological inhibition of bacterial beta-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo","volume":"139","year":"2019","journal-title":"Pharmacol Res."},{"issue":"6","key":"b12","first-page":"291","article-title":"Active substances in pharmaceutical plants; methods to determine plant tinctures; contributions to a supplementary issue of the homoiopathic pharmacopeia","volume":"2","year":"1952","journal-title":"Arzneimittelforschung"},{"key":"b13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jpba.2016.05.034","article-title":"Recent advances in the analysis of flavonolignans of Silybum marianum","volume":"130","year":"2016","journal-title":"J Pharm Biomed Anal."},{"issue":"14","key":"b14","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2165\/00003495-200161140-00003","article-title":"The use of silymarin in the treatment of liver diseases","volume":"61","year":"2001","journal-title":"Drugs"},{"issue":"6","key":"b15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2893.2005.00636.x","article-title":"Silymarin treatment of viral hepatitis: A systematic review","volume":"12","year":"2005","journal-title":"J Viral Hepat."},{"issue":"2","key":"b16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1534735407301632","article-title":"Advances in the use of milk thistle (Silybum marianum)","volume":"6","year":"2007","journal-title":"Integr Cancer Ther."},{"issue":"3","key":"b17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1248\/bpb.17.443","article-title":"Silymarin and its components are inhibitors of beta-glucuronidase","volume":"17","year":"1994","journal-title":"Biol Pharm Bull."},{"key":"b18","journal-title":"Sample Size Calculator"},{"issue":"6","key":"b19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","year":"1982","journal-title":"Am J Clin Oncol."},{"key":"b20","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/jco.2004.22.90140.3576","article-title":"Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer\u2014A pooled analysis of 254 patients included in 2 randomised trials","volume":"22","year":"2004","journal-title":"J Clin Oncol."},{"key":"b21","first-page":"34","article-title":"CPT-11 in the treatment of colorectal cancer: Clinical efficacy and safety profile","volume":"23","year":"1996","journal-title":"Semin Oncol."},{"issue":"10","key":"b22","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/sj.bjc.6605938","article-title":"A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer","volume":"103","year":"2010","journal-title":"Br J Cancer"},{"issue":"5","key":"b23","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1007\/s10637-011-9721-6","article-title":"Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: A retrospective Italian study","volume":"30","year":"2012","journal-title":"Invest New Drugs"},{"issue":"3","key":"b24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/bjc.2011.594","article-title":"Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab versus FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable\/metastatic colorectal cancer (mCRC)","volume":"106","year":"2012","journal-title":"Br J Cancer"},{"issue":"6","key":"b25","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.ejca.2012.12.011","article-title":"Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13\/0503 study)","volume":"49","year":"2013","journal-title":"Eur J Cancer"},{"key":"b26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1756-0500-7-260","article-title":"FOLFIRI\u00ae and bevacizumab in first-line treatment for colorectal cancer patients: Safety, efficacy and genetic polymorphisms","volume":"7","year":"2014","journal-title":"BMC Res Notes"},{"issue":"10","key":"b27","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial","volume":"15","year":"2014","journal-title":"Lancet Oncol."},{"issue":"12","key":"b28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2468-1253(18)30269-3","article-title":"Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: A multicentre, open-label, randomised controlled trial","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"5","key":"b29","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s10147-011-0213-7","article-title":"Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma","volume":"16","year":"2011","journal-title":"Int J Clin Oncol."},{"issue":"5","key":"b30","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00280-013-2292-9","article-title":"FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: A JACCRO CC-03 multicenter phase II study","volume":"72","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"issue":"2","key":"b31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trsl.2013.12.009","article-title":"Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil\/leucovorin with irinotecan in a first-line setting","volume":"164","year":"2014","journal-title":"Transl Res."},{"issue":"5","key":"b32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jcph.246","article-title":"Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms","volume":"54","year":"2014","journal-title":"J Clin Pharmacol."},{"issue":"8","key":"b33","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","article-title":"Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)","volume":"27","year":"2016","journal-title":"Ann Oncol."}],"container-title":["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/uploads\/attached\/file\/20220621\/20220621145116_83715.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T21:39:02Z","timestamp":1733521142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v28n7-8\/48469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9,7]]}},"alternative-id":["0965-0407(20210907)28:7L.801;1-"],"URL":"https:\/\/doi.org\/10.3727\/096504021x16218531628569","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,7]]}}}